Wells Fargo & Company In8 Bio, Inc. Call Options Transaction History
Wells Fargo & Company
- $410 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding INAB
# of Institutions
33Shares Held
8.64MCall Options Held
0Put Options Held
0-
Aigh Capital Management LLC Baltimore, MD2.87MShares$2.44 Million1.37% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.42MShares$1.21 Million0.0% of portfolio
-
Ensign Peak Advisors, Inc Salt Lake City, UT1.12MShares$950,5260.0% of portfolio
-
683 Capital Management, LLC New York, NY615KShares$522,5400.06% of portfolio
-
Sigma Planning Corp Ann Arbor, MI515KShares$437,8180.02% of portfolio
About IN8BIO, INC.
- Ticker INAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 24,502,200
- Market Cap $20.8M
- Description
- IN8bio, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of gamma-delta T cell therapies for the treatment of cancers. Its lead product candidate includes INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of...